Autocrine signals promote osteoblast survival in culture.
We have studied the survival requirements of osteoblasts to test the hypothesis that osteoblasts undergo programmed cell death (PCD) or apoptosis unless they are continuously signalled by other cells not to do so. Osteoblasts survived for 6 days in culture at high cell density in the absence of other cell types, serum or exogenous proteins, but they died with the morphological features of apoptosis in these conditions at low cell density. Osteoblast survival was enhanced during the first 2 days of culture by the addition of the sulphydryl compound, cysteine to the culture medium which was converted intracellularly to the antioxidant glutathione. Catalase, an enzyme decomposing hydrogen peroxide, also protected the cells, whereas superoxide dismutase had no effect. Therefore, osteoblasts in culture are sensitive to toxic compounds derived from molecular oxygen, i.e. hydroxyl radicals or hydrogen peroxide spontaneously generated in CMRL medium containing ascorbate and ferrous ions. Conditioned medium from high density cultures prevented osteoblast apoptosis in low density cultures, as long as antioxidants were also present. The enhancing effect of conditioned medium on osteoblast survival was prevented by neutralizing antibodies to insulin-like growth factor-I (IGF-I) and IGF-II but not by antibodies to either platelet-derived growth factor (PDGF) or basic fibroblast growth factor (bFGF). These results suggest that in addition to regulating cell growth and differentiation, IGF-I and IGF-II also function as survival factors for osteoblasts. Our data also indicate that antioxidants are required for osteoblast survival and that they enhance growth factor mediated osteoblast survival.
Tumber
A
A
Bone Biology Unit, Department of Orthodontics and Paediatric Dentistry, Guy's, King's and St Thomas' Hospital's Medical and Dental Schools, Guy's Hospital, St Thomas' Street, London SE1 9RT, UK.
Meikle
M C
MC
Hill
P A
PA
D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D019898:Autocrine Communication; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002469:Cell Separation; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free; D003545:Cysteine / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D020287:In Situ Nick-End Labeling; D007334:Insulin-Like Growth Factor I / Q000276:immunology; D007335:Insulin-Like Growth Factor II / Q000276:immunology; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000502:physiology*; D012886:Skull / Q000166:cytology; D018709:Statistics, Nonparametric; D013482:Superoxide Dismutase / Q000494:pharmacology; D013936:Thymidine / Q000494:pharmacology
D000906:Antibodies; D000975:Antioxidants; D016895:Culture Media, Serum-Free; D019328:Buthionine Sulfoximine; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione; D003545:Cysteine; D013936:Thymidine